I-Mab (0VY.F)
| Previous Close | 1.6600 |
| Open | 1.6300 |
| Bid | 1.6300 x N/A |
| Ask | 1.6600 x N/A |
| Day's Range | 1.6300 - 1.6300 |
| 52 Week Range | 1.0900 - 3.0400 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 131.544M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
I-MAB Filed 2023 Annual Report on Form 20-F
I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.
- PR Newswire
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.
- PR Newswire
I-Mab Announces Closing of the Divestiture of Business Operations in China
I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the "Transaction") have been either satisfied or waived and accordingly, the Transaction has successfully closed.
